Page last updated: 2024-08-22

cadmium and Myelodysplastic Syndromes

cadmium has been researched along with Myelodysplastic Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Angel, CR; Bishop, MR; Iversen, PL; Mata, JE; Swanson, SA; Tarantolo, SR	1

Trials

1 trial(s) available for cadmium and Myelodysplastic Syndromes

Article	Year
Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. Journal of toxicology. Clinical toxicology, 2000, Volume: 38, Issue:4 Topics: Cadmium; Chelating Agents; Copper; Dose-Response Relationship, Drug; Erythrocyte Count; Humans; Infusions, Intravenous; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Oligodeoxyribonucleotides, Antisense; RNA, Messenger; Spectrophotometry, Atomic; Thionucleotides; Tumor Suppressor Protein p53; Zinc	2000

Article

Year

Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment.

Journal of toxicology. Clinical toxicology, 2000, Volume: 38, Issue:4

Topics: Cadmium; Chelating Agents; Copper; Dose-Response Relationship, Drug; Erythrocyte Count; Humans; Infusions, Intravenous; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Oligodeoxyribonucleotides, Antisense; RNA, Messenger; Spectrophotometry, Atomic; Thionucleotides; Tumor Suppressor Protein p53; Zinc

2000